Hangzhou Huajin Pharmaceutical

Hangzhou Huajin Pharmaceutical is a clinical-stage biopharmaceutical company headquartered in Hangzhou, China, dedicated to the development of first-in-class small molecule therapeutics for oncology. The company's primary focus is on cancer metabolism and the tumor microenvironment, aiming to address unmet medical needs in solid tumors. Its lead program, HJ-001, is a potent inhibitor of Lactate Dehydrogenase A (LDHA) and is currently in Phase 1 clinical trials. Huajin Pharmaceutical utilizes its specialized research platform to identify novel metabolic targets and advance a pipeline of innovative candidates. The company is led by a team of experienced scientists with expertise in drug discovery and clinical development.